TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

211 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-01

Study Completion Date

2017-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with parent study CTN-0051, which assessed the comparative effectiveness of extended release injectable naltrexone (XR-NTX, Vivitrol®), an opioid antagonist recently approved and indicated for the prevention of relapse to opioid dependence, versus buprenorphine-naloxone (BUP-NX, Suboxone®), a high affinity partial agonist indicated for maintenance treatment of opioid dependence, as pharmacotherapeutic aids to recovery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946

Heroin Dependence Opioid-Related Disorders

COMPLETED PHASE4

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

NCT03232346

Opioid-use Disorder

COMPLETED PHASE3

Phone Interview to Prevent Recurring Opioid Overdoses

NCT02282306

Overdose Opioid-related Disorders Drug Addiction +5 more

COMPLETED NA

Medication-Assisted Treatment for Youth With Substance Use Disorders

NCT02593474

Opioid Use Disorder Opioid Dependence

COMPLETED PHASE1

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

NCT00675532

Drug Dependence

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participant recruitment will begin after recruitment for CTN-0051 has been completed. Opioid use disorder patients will be recruited prior to leaving detoxification and/or short-term residential programs. Screening and baseline data (focused on demographics, diagnosis and service utilization) will be collected prior to discharge, and follow-up data (focused on opioid use) will be collected at weeks 1, 4 and 8 following discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Opioid Use Disorder Patients

Treatment As Usual

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment As Usual

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older;
* Meet DSM-5 criteria for opioid-use disorder (heroin or prescription opioids);
* Have used opioids other than as specifically prescribed within thirty days prior to consent
* Seeking treatment for opioid dependence;
* Able to provide written informed consent;
* Able to speak English sufficiently to understand the study procedures.

Exclusion Criteria

* Serious medical, psychiatric or substance use disorder that, in the opinion of the Site PI, would make participation hazardous to the participant, compromise study findings or prevent the participant from completing the study;
* Suicidal or homicidal ideation that requires immediate attention;
* Maintenance on methadone at doses of 30mg or greater at the time of signing consent;
* Presence of pain of sufficient severity as to require ongoing pain management with opioids;
* Pending legal action or other reasons that might prevent an individual from completing the study;
* If female, currently pregnant or breastfeeding or planning on conception;
* Prior participation in parent trial CTN-0051

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No